. 2021 Jan 30;27(1):87–96. doi: 10.5056/jnm20061

Table 5.

Changes in Dyspepsia-specific Quality of Life Scores From Baseline at Week 4

NDI-K scores	Mosapride citrate SR group (n = 51)	Mosapride citrate CR group (n = 49)	Intergroup P-value
Total
Baseline	276.34 ± 76.11	288.57 ± 70.79	0.465^b
Week 4	340.16 ± 80.48	355.69 ± 85.46
Change^a	63.82 ± 82.91	67.12 ± 81.11	> 0.999^b
In group P-value	< 0.001^c	< 0.001^d
Tension/sleep
Baseline	58.14 ± 19.00	60.22 ± 17.16	0.567^e
Week 4	73.38 ± 17.55	75.45 ± 19.62
Change^a	15.23 ± 20.27	15.23 ± 18.59	0.890^b
In group P-value	< 0.001^c	< 0.001^d
Interference with daily activities
Baseline	57.23 ± 16.14	58.43 ± 17.56	0.721^e
Week 4	65.61 ± 18.38	69.23 ± 18.86
Change^a	8.38 ± 18.94	10.79 ± 19.38	0.497^b
In group P-value	< 0.001^c	< 0.001^d
Eating/drinking
Baseline	56.78 ± 19.45	59.01 ± 16.74	0.541^e
Week 4	71.46 ± 19.11	74.04 ± 20.47
Change^a	14.68 ± 18.98	15.02 ± 20.22	0.909^b
In group P-value	< 0.001^c	< 0.001^d
Knowledge/control
Baseline	46.51 ± 17.72	51.15 ± 15.68	0.145^b
Week 4	61.34 ± 18.00	64.92 ± 18.00
Change^a	14.83 ± 20.28	13.78 ± 17.62	0.783^e
In group P-value	< 0.001^d	< 0.001^d
Work/study
Baseline	57.68 ± 17.26	59.75 ± 17.49	0.553^e
Week 4	68.38 ± 20.26	72.05 ± 19.71
Change^a	10.70 ± 20.58	12.30 ± 20.11	0.984^b
In group P-value	< 0.001^c	< 0.001^d

NDI-K, Nepean Dyspepsia Index-Korean version.

^aChanges in score related to symptoms (week 4-baseline).

^bTwo-sample t test.

^cWilcoxon signed rank test.

^dPaired t test.

^eWilcoxon rank sum test.